Future healthcare for patients with the common pain disorder 'fibromyalgia syndrome' - fundamental changes based on the discovery of an immune cause

Published on February 5, 2026

Future Healthc J. 2025 Dec 15;12(4):100480. doi: 10.1016/j.fhj.2025.100480. eCollection 2025 Dec.

ABSTRACT

Recent laboratory advances have allowed re-conceptualising fibromyalgia syndrome, a common, severe chronic widespread pain condition, as an immune-mediated disease. This article summarises key findings and their implications for preventative strategies and future healthcare advances and their costs.

PMID:41631133 | PMC:PMC12861675 | DOI:10.1016/j.fhj.2025.100480

Continue reading on website
s41598-026-38137-y_reference.pdf
Other news

Expanding the Genetic Landscape of Congenital Insensitivity to Pain

February 5, 2026
Neurol Genet. 2026 Feb 2;12(1):e200346. doi: 10.1212/NXG.0000000000200346. eCollection 2026 Feb.ABSTRACTOBJECTIVES: Congenital insensitivity to pain (CIP) is a rare sensory neuropathy marked by absent nociception that predisposes patients to injuries and complications. Variants in genes, particularly PRDM12, underlie the condition. We investigated the molecular basis of CIP in 2 unrelated families

Human Dorsal Root Ganglia Neuronal Cell Line to Study Nociceptive Signaling: A New Pipeline for Pain Therapy

February 5, 2026
FASEB J. 2026 Feb 15;40(3):e71528. doi: 10.1096/fj.202503698R.ABSTRACTNociceptive afferent neurons within the dorsal root ganglion (DRG) detect and relay painful peripheral stimuli, and the malfunctioning of this process leads to sustained pain states. Animal model studies have been invaluable for demonstrating the importance of the DRG nociceptor in pain sensation and the development of related a